Abstract
To effectively inform infectious disease control strategies, accurate knowledge of the pathogen’s transmission dynamics is required. The infection incidence, which describes the number of new infections in a given time interval (e.g., per day or per week), is fundamental to understanding transmission dynamics, and can be used to estimate the time-varying reproduction number and the severity (e.g., the infection fatality ratio) of a disease. The timings of infections are rarely known and so estimates of the infection incidence often rely on measurements of other quantities amenable to surveillance. Case-based surveillance, in which infected individuals are identified by a positive test, is the pre-dominant form of surveillance for many pathogens, and was used extensively during the COVID-19 pandemic. However, there can be many biases present in case-based surveillance indicators due to, for example, test sensitivity and specificity, changing testing behaviours, and the co-circulation of pathogens with similar symptom profiles. Without a full understanding of the process by which surveillance systems generate data, robust estimates of the infection incidence, time-varying reproduction number, and severity based on these data cannot be made. Here we develop a mathematical description of case-based surveillance of infectious diseases. By considering realistic epidemiological parameters and situations, we demonstrate potential biases in common surveillance indicators based on case-based surveillance data. The description is highly general and could be applied to a diverse set of pathogens and situations. The mathematical description could be used to inform inference of infection incidence using existing data, with a full understanding of where bias and uncertainty will be present in any such analysis. Future surveillance strategies could be designed to minimise these sources of bias and uncertainty, providing more accurate estimates of a pathogen’s transmission dynamics and, ultimately, more targeted application of public health measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This is a simulation study and so there is no data.
